Insights into parasites and COVID-19 co-infections in Iran: a systematic review.
Trans R Soc Trop Med Hyg
; 118(6): 350-358, 2024 Jun 04.
Article
en En
| MEDLINE
| ID: mdl-38288655
ABSTRACT
BACKGROUND:
It is well-documented that using immunosuppressive drugs such as corticosteroids or cytokine blockers in treating coronavirus disease 2019 (COVID-19) increases the risk of co-infections. Here we systematically summarized the cases of COVID-19-associated parasitic infections (CAPIs) in Iran.METHODS:
From 19 February 2020 to 10 May 2023, all studies on Iranian patients suffering from CAPIs were collected from several databases using a systematic search strategy.RESULTS:
Of 540 records, 11 studies remained for data extraction. In this research, most of the studies were related to Lophomonas and Toxoplasma. Of 411 cases of CAPIs, toxoplasmosis (385 [93.7%]) had the highest rate of infection among Iranian patients, followed by blastocystosis (15 [3.6%]), fascioliasis (4 [0.97%]), leishmaniasis (3 [0.7%]), lophomoniasis (3 [0.7%]) and strongyloidiasis (1 [0.2%]). In general, Blastocystis enhanced diarrhoea in patients with COVID-19. Lophomonas, Toxoplasma and Strongyloides increased the severity of COVID-19, but Fasciola decreased its intensity. Patients with a history of cutaneous leishmaniasis showed mild symptoms of COVID-19. Also, patients with a prior history of hydatid cysts were not affected by COVID-19.CONCLUSIONS:
Due to the similar symptoms of some parasitic diseases and COVID-19 and immunosuppressive treatment regimens in these patients that may cause the reactivation or recurrence of parasitic infections, early diagnosis and treatment are required.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Enfermedades Parasitarias
/
Coinfección
/
SARS-CoV-2
/
COVID-19
Tipo de estudio:
Screening_studies
/
Systematic_reviews
Límite:
Animals
/
Humans
País/Región como asunto:
Asia
Idioma:
En
Revista:
Trans R Soc Trop Med Hyg
Año:
2024
Tipo del documento:
Article
País de afiliación:
Irán